AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02305264
Drug: 18F-DPA-714 and 18F-FDG
RxNorm normalized name: (18F)-FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Positron emission tomography (PET) imaging following the injection of 2 radiotracers (here considered as the drugs): 1) 18F-DPA-714 ii) 18F-FDG. PET -18F-DPA-714, dose 5mCi (185MBq), will be injected via an arm intravenous catheter.~18F-FDG , dose 5mci(185MBq), will be injected via an arm intravenous catheter.
Trial: NCT03055936
Drug: Carbidopa
RxNorm normalized name: Carbidopa
DrugBank: Carbidopa (DB00190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbidopa 12.5 mg or 25 mg or 65 mg
Trial: NCT03055936
Drug: ODM-104
RxNorm normalized name: ODM-203
DrugBank: ODM-203 (DB16843)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ODM-104 50 mg or 100 mg
Trial: NCT04164238
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab Injection
Trial: NCT04164238
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel Injection
Trial: NCT04164238
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin Injection
Trial: NCT04164238
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin injection
Trial: NCT04164238
Drug: 5-fu
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fu injection
Trial: NCT03207399
Drug: Epclusa
RxNorm normalized name: Epclusa
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will be treated with this drug for 12 weeks post lung transplant.
Trial: NCT06143761
Drug: PD-1 inhibitor+carboplatin+albumin-bound paclitaxel
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A comparative evaluation of patient prognosis between those who received neoadjuvant chemoimmunotherapy-surgery treatment and those who underwent surgery alone.
Trial: NCT04136028
Drug: Kineret
RxNorm normalized name: Kineret
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Kineret at a dose of 8 mg/kg per day subcutaneously daily, every day at the same time
Trial: NCT02669719
Drug: pemetrexed and carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Chemotherapy with 4-6 cycles of pemetrexed and carboplatin as first-line induction chemotherapy followed by pemetrexed as maintenance therapy.
Trial: NCT03271554
Drug: Alectinib
RxNorm normalized name: Alectinib
DrugBank: Alectinib (DB11363)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: According to local labeling the recommended dose of alectinib is 600 mg given orally, twice daily with food (total daily dose of 1200 mg).
Trial: NCT00688103
Drug: ETN Alone
RxNorm normalized name: ETN
DrugBank: Erythrityl tetranitrate (DB01613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etanercept (25 mg, twice/week, s.c.)
Trial: NCT02904031
Drug: 5-fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02904031
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02904031
Drug: panitumumab
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04094909
Drug: Rh-endostatin
RxNorm normalized name: Pentostatin
DrugBank: Endostatin (DB06423)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Squamous NSCLC: Rh-endostatin+Pembrolizumab+carboplatin or cisplatin +\[nab\]-paclitaxel during the treatment. Rh-endostatin+Pembrolizumab during the maintenance period.~Non-squamous NSCLC: Rh-endostatin+Pembrolizumab+carboplatin or cisplatin +pemetrexed during the treatment. Rh-endostatin+Pembrolizumab + pemetrexed during the maintenance period.
Trial: NCT00701311
Drug: CC-10004
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-10004 20 mg per day
Trial: NCT01924234
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01712685
Drug: 18F-VM4-037
RxNorm normalized name: (18F)-Fluoride
DrugBank: VM4-037 (DB15319)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug being tested for use in cancer imaging studies. It may help tumor tissue show up more clearly during scans.
Trial: NCT03472963
Drug: Single dose of Genvoya® and a single 800 mg dose of Darunavir®
DrugBank: Darunavir (DB01264)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Men will be instructed to take Single dose of Genvoya® and a single 800 mg dose of Darunavir® per oral
Trial: NCT04186663
Drug: Silver Diamine Fluoride
RxNorm normalized name: silver fluoride
DrugBank: Silver nitrate (DB11080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 38% aqueous silver diamine fluoride \[Ag(NH3)\]2F, CAS RN 33040-28-7
Trial: NCT00179608
Drug: CC-5013
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00805012
Drug: docetaxel+CDDP
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: docetaxel+CDDP
Trial: NCT00805012
Drug: docetaxel+S-1
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: docetaxel+S-1
Trial: NCT01783847
Drug: Recombinant human erythropoietin (EPO)
RxNorm normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4000 units per vial
Trial: NCT01783847
Drug: Methyl prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250 mg every 6 hours for 3 days.
Trial: NCT01871285
Drug: Buprenorphine
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01203696
Drug: Amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For patient with suboptimal angina control: oral 2.5-10mg daily
Trial: NCT01203696
Drug: Amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For patient with suboptimal BP control: 2.5-10mg daily po
Trial: NCT01871285
Drug: Oxycodone
RxNorm normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone extended-release (ER) or immediate-release (IR) 5, 10, 15, 20, and 30 mg over-encapsulated oral tablets
Trial: NCT01871285
Drug: Morphine sulfate
RxNorm normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine sulfate 15, 30, and 60 mg ER or 15 and 30 mg IR over-encapsulated oral tablets
Trial: NCT03444584
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral dose of metformin tablet (maximum tolerated dose \[MTD\] \> 1 g).
Trial: NCT04435795
Drug: Normal Saline intranasal and placebo inhaler
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline intranasal BID and Placebo 3 puff MDI inhaled BID
Trial: NCT04435795
Drug: Ciclesonide
RxNorm normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciclesonide 600mcg BID inhaled with aero chamber
Trial: NCT04435795
Drug: Ciclesonide nasal
RxNorm normalized name: ciclesonide nasal
DrugBank: Ciclesonide (DB01410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intranasal ciclesonide 200 mcg DIE
Trial: NCT01461616
Drug: Detemir
RxNorm normalized name: Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: equal doses of NPH insulin, insulin Detemir and insulin glargine injection
Trial: NCT01461616
Drug: Glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: equal doses of NPH insulin, insulin Detemir and insulin glargine injection
Trial: NCT00691405
Drug: Arformoterol tartrate inhalation solution
RxNorm normalized name: ARFORMOTEROL TARTRATE 15 ug in 2 mL RESPIRATORY (INHALATION) SOLUTION [Arformoterol Tartrate Inhalation Solution]
DrugBank: Arformoterol (DB01274)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arformoterol 5 mcg BID
Trial: NCT02338921
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 100mg qd per oral during 24months~compared with other treatment groups
Trial: NCT02338921
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10mg qd per oral during 24months~compared with other treatment groups
Trial: NCT02338921
Drug: Lobeglitazone
RxNorm normalized name: lobeglitazone
DrugBank: Lobeglitazone (DB09198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5mg qd per oral during 24months~compared with other treatment groups
Trial: NCT02338921
Drug: Glimepirde
RxNorm normalized name: Glimepiride
DrugBank: Lime (citrus) (DB10635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02338921
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00691405
Drug: Arformoterol tartrate inhalation solution
RxNorm normalized name: ARFORMOTEROL TARTRATE 15 ug in 2 mL RESPIRATORY (INHALATION) SOLUTION [Arformoterol Tartrate Inhalation Solution]
DrugBank: Arformoterol (DB01274)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arformoterol 15 mcg BID
Trial: NCT00691405
Drug: Arformoterol tartrate inhalation solution
RxNorm normalized name: ARFORMOTEROL TARTRATE 15 ug in 2 mL RESPIRATORY (INHALATION) SOLUTION [Arformoterol Tartrate Inhalation Solution]
DrugBank: Arformoterol (DB01274)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arformoterol 25 mcg BID
Trial: NCT02459509
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Either 2mcg/kg or 4mcg/kg of intranasal dexmedetomidine will be given to assess efficacy of preoperative sedation
Trial: NCT03878082
Drug: Propacetamol 1g
RxNorm normalized name: 1,2,3-propanetriol, 2-(4-aminobenzoate)
DrugBank: Propacetamol (DB09288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pain control with IVPCA and propacetamol 1g every 6 hours for 2 days
Trial: NCT03878082
Drug: Propacetamol 2g
RxNorm normalized name: 1,2,3-propanetriol, 2-(4-aminobenzoate)
DrugBank: Propacetamol (DB09288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pain control with IVPCA and propacetamol 2g every 6 hours for 2 days
Trial: NCT03595449
Drug: Lidocaine jelly
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: lidocaine 2% jelly applied during Mohs surgery
Trial: NCT00691405
Drug: Arformoterol tartrate inhalation solution
RxNorm normalized name: ARFORMOTEROL TARTRATE 15 ug in 2 mL RESPIRATORY (INHALATION) SOLUTION [Arformoterol Tartrate Inhalation Solution]
DrugBank: Arformoterol (DB01274)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arformoterol 15 mcg QD
Trial: NCT00691405
Drug: Arformoterol tartrate inhalation solution
RxNorm normalized name: ARFORMOTEROL TARTRATE 15 ug in 2 mL RESPIRATORY (INHALATION) SOLUTION [Arformoterol Tartrate Inhalation Solution]
DrugBank: Arformoterol (DB01274)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arformoterol 25 mcg QD
Trial: NCT00691405
Drug: Arformoterol tartrate inhalation solution
RxNorm normalized name: ARFORMOTEROL TARTRATE 15 ug in 2 mL RESPIRATORY (INHALATION) SOLUTION [Arformoterol Tartrate Inhalation Solution]
DrugBank: Arformoterol (DB01274)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arformoterol 50 mcg QD
Trial: NCT05365074
Drug: Chloroprocaine Injection
RxNorm normalized name: chloroprocaine Injection
DrugBank: Chloroprocaine (DB01161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spinal anesthesia with 50 mg of 1% Chloroprocaine
Trial: NCT03715582
Drug: trimetazidine
RxNorm normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pills of masking drug - trimetazidine
Trial: NCT00433459
Drug: dacarbazine
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: drug is used in first line treatment in combination (COPDAC)
Trial: NCT00433459
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: drug is used in first line treatment in combination (OEPA, COPP or COPDAC)
Trial: NCT00433459
Drug: procarbazine hydrochloride
RxNorm normalized name: Procarbazine Hydrochloride
DrugBank: Procarbazine (DB01168)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: drug is used in first line treatment in combination (COPP)
Trial: NCT00433459
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: drug is used in first line treatment in combination (OEPA, COPP or COPDAC)
Trial: NCT00006373
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide IV 500 mg/m2/day over 24 hours Days -5, -4, -3
Trial: NCT00006373
Drug: ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ifosfamide 3,333 mg/m2/day IV over 2 hours (total dose 10,000 mg/m2)Days -8, -7, -6
Trial: NCT00006373
Drug: topotecan hydrochloride
RxNorm normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topotecan 21.3 mg/m2/day (total dose 64 mg/m2 ) IV over 30 minutes Days -8, -7, -6
Trial: NCT00006373
Drug: Mesna
RxNorm normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mesna 1,111 mg/m2/dose IV over 30 minutes; 30 minutes before and 4 and 8 hours after ifosfamide (total dose 10,000 mg/m2) Days -8, -7, -6
Trial: NCT00121199
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02749409
Drug: Parecoxib
RxNorm normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Trial: NCT02749409
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00121199
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00663338
Drug: Rotigotine
RxNorm normalized name: Rotigotine
DrugBank: Rotigotine (DB05271)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rotigotine 9.0mg patch (equivalent to 4mg/24hr transdermal absorption) once daily during the treatment phase.
Trial: NCT00117234
Drug: darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02875678
Drug: ABX-1431
RxNorm normalized name: ABX-1431
DrugBank: ABX-1431 (DB16036)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose ABX-1431
Trial: NCT01256476
Drug: pitavastatin
RxNorm normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pitavastatin 4 mg once daily (QD)
Trial: NCT00206661
Drug: Sargramostim (Leukine)
RxNorm normalized name: Sargramostim
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 mcg sargramostim with and without corticosteroids
Trial: NCT00206661
Drug: Sargramostim (Leukine)
RxNorm normalized name: Sargramostim
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6 mcg sargramostim with and without corticosteroids
Trial: NCT02018861
Drug: Parsaclisib
RxNorm normalized name: Parsaclisib
DrugBank: Parsaclisib (DB14867)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03572478
Drug: Rucaparib
RxNorm normalized name: Rucaparib
DrugBank: Rucaparib (DB12332)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 600 mg taken by mouth twice daily.
Trial: NCT03572478
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 480 mg given by intravenous (IV) infusion every 4 weeks.
Trial: NCT02018861
Drug: Itacitinib
RxNorm normalized name: itacitinib
DrugBank: Itacitinib (DB12154)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02018861
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02018861
Drug: Ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02018861
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02018861
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01642186
Drug: everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01642186
Drug: letrozole plus leuprolide
RxNorm normalized name: Letrozole
DrugBank: Leuprolide (DB00007)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01642186
Drug: combination of everolimus, letrozole and leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02536911
Drug: eliglustat
RxNorm normalized name: Eliglustat
DrugBank: Eliglustat (DB09039)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical form: capsule~Route of administration: oral
Trial: NCT02133157
Drug: Sulfatinib
RxNorm normalized name: SULFATINIB
DrugBank: Surufatinib (DB15106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfatinib is a capsule in the form of25, 50mg , 100mg; oral, once a day
Trial: NCT01685203
Drug: Ribavirin (RBV)
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablet
Trial: NCT04727775
Drug: Favipiravir
RxNorm normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Antiviral drugs
Trial: NCT02293148
Drug: Moxifloxacin 400 mg
RxNorm normalized name: moxifloxacin 400 MG
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oblong, dull red, film-coated, convex tablets with M400 on one side
Trial: NCT02293148
Drug: Placebo matching Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsule shaped white film coated tablet as matching placebo for Moxifloxacin
Trial: NCT04727775
Drug: Remdesivir
RxNorm normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Antiviral drugs
Trial: NCT00252733
Drug: candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 32 mg once daily oral tablet given over 60 months
Trial: NCT02635360
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200 mg of study drug is given through intravenous (IV) administration once every 21 days for 3 months.
Trial: NCT02635360
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg of chemotherapy drug will be given weekly for 5-6 weeks.
Trial: NCT02970331
Drug: pefcalcitol ointment, 0.005%
DrugBank: Pefcalcitol (DB11786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pefcalcitol ointment, 0.005%
Trial: NCT02550470
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02315352
Drug: L-PZQ ODT
RxNorm normalized name: L-PZQ
DrugBank: (R)-Praziquantel (DB11749)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-PZQ ODT (MSC2499550A) tablet at a dose of 150 milligram (mg) put and disintegrated in the mouth without water
Trial: NCT02315352
Drug: Rac-PZQ ODT
RxNorm normalized name: rac-dobutamine
DrugBank: Dobutamine (DB00841)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rac-PZQ ODT (MSC1028703A) tablet at a dose of 150 mg put and disintegrated in the mouth without water
Trial: NCT02315352
Drug: L-PZQ ODT
RxNorm normalized name: L-PZQ
DrugBank: (R)-Praziquantel (DB11749)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-PZQ (MSC2499550A) tablet at a dose of 150 mg dispersed in water
Trial: NCT02315352
Drug: Rac-PZQ ODT
RxNorm normalized name: rac-dobutamine
DrugBank: Dobutamine (DB00841)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rac-PZQ ODT (MSC1028703A) tablet at a dose of 150 mg dispersed in water
Trial: NCT00211497
Drug: MBI 226 Acne Solutions
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00589082
Drug: DaunoXome
RxNorm normalized name: DaunoXome
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00589082
Drug: Daunorubicine
RxNorm normalized name: Daunorubicine
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00947557
Drug: Dutogliptin
RxNorm normalized name: Dutogliptin
DrugBank: Dutogliptin (DB11723)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dutogliptin oral administration once daily on background of glimepiride with or without metformin
Trial: NCT04040816
Drug: SAP-001
RxNorm normalized name: HURA CREPITANS SAP
DrugBank: AP-001 (DB18511)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAP-001 or placebo treatment in a 4:1 randomization ratio
Trial: NCT00321009
Drug: Enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no